Early Hospital Readmissions and Mortality in Patients with Decompensated Cirrhosis enrolled in a Large National Health Insurance Administrative Database
AASLD LiverLearning®, Steven Scaglione, 144641
Predictors Of 30-Day Readmission In Patients Hospitalized With Decompensated Cirrhosis in a Large State Based Inpatient Sample
AASLD LiverLearning®, Sehem Ghazala, 144642
Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir + ribavirin for treatment of HCV genotype 1b compensated cirrhosis in patients aged 65 years or older
AASLD LiverLearning®, Anca Trifan, 144898
Mental Health Predictors of All Oral Direct Acting Antiviral Receipt in Individuals with Hepatitis C Virus Infection
AASLD LiverLearning®, Jennifer Kramer, 144643
Efficacy and safety of ombitasvir (OBV) and ritonavir boosted paritaprevir (PRV/r) with or without dasabuvir (DSV) regimens in genotype 1 or 4 HCV infected patients. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, Jiannis Vlachogiannakos, 144899
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection in patients with renal dysfunction; From real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144900
A Creatinine-Modified Child-Turcotte-Pugh (CTP-Cr) outperforms the original CTP and Model for End Stage Liver Disease (MELD) for predicting short- and long-term transplant-free survival in a national cohort with cirrhosis.
AASLD LiverLearning®, David Kaplan, 144657
Hepatitis A and B vaccination rates in patients with chronic liver disease: A Quality Improvement Project
AASLD LiverLearning®, Moaz Sial, 144658
Changes in Liver Stiffness and Clinical Outcomes after SVR in Patients with Advanced Fibrosis or Cirrhosis from Hepatitis C Virus
AASLD LiverLearning®, Sonal Kumar, 144914
Eliminating Hepatitis C in Spain: Bridging from the National Health Plan
AASLD LiverLearning®, Maria Buti, 144659
Ledipasvir/sofosbuvir is effective and well tolerated in post-kidney transplant patients with chronic hepatitis C virus.
AASLD LiverLearning®, Amilcar Morales-Cardona, 144915
Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience From the Trio Network
AASLD LiverLearning®, Kevin Korenblat, 144916
Peak Immunogenicity of Two Doses of Investigational HEPLISAV-B™ in Difficult to Vaccinate Individuals: Seroprotection Rates in Three Phase 3 Trials
AASLD LiverLearning®, Sam Jackson, 144672
Racial disparity in the Prevalence of Hepatitis B Virus (HBV) Immunity in the United States: Results from the National Health and Nutrition Examination Survey 2011-2014
AASLD LiverLearning®, Hyunseok Kim, 144673
Low Rates of Hepatitis B Virus (HBV) Screening and Low Rates of HBV Awareness Among High Risk Patients at a Large, Urban, Safety-Net Hospital
AASLD LiverLearning®, Robert Wong, 144674
ATTIRE Stage 1 - Albumin To prevenT Infection in chronic liveR failurE : a single-arm feasibility trial of targeted therapy with 20% Human Albumin Solution
AASLD LiverLearning®, Louise China, 144930
Increased risk of hepatocellular carcinoma in patients with low-level viremia than maintained virological remission in patients receiving entecavir monotherapy
AASLD LiverLearning®, jung hee kim, 144675
Increased risk of in-hospital sepsis related mortality and non-ICU death in patients with cirrhosis after cardiac arrest: A retrospective-prospective nested case-control study
AASLD LiverLearning®, Megan Reinders, 144931
Assessment of Presence and Dynamic evolution of Organ Failures during Early Intensive Management by MERCIC model can guide inappropriate ‘Futile Care’ in the first week in Critically Ill Cirrhotics
AASLD LiverLearning®, RAKHI MAIWALL, 144932
Jagged1 is associated with poor prognosis of HBV-related liver cancer
AASLD LiverLearning®, Kazunori Kawaguchi, 144688
Serum Ceruloplasmin can be applied to assess liver fibrosis in chronic hepatitis B virus patients with normal or minimally raised ALT
AASLD LiverLearning®, Da-Wu Zeng, 144689
Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBC positive patients undergoing rituximab-based chemotherapy for non-Hodgkin b cell lymphoma - final results
AASLD LiverLearning®, Pietro Lampertico, 144690
Etiology of chronic liver disease has no impact on the course and outcome of patients with Acute on Chronic Liver Failure
AASLD LiverLearning®, Yogesh Kumar Chawla, 144946
A Primary Care and Community-Based Hepatitis B Screening and Linkage-to-Care Program in New Jersey
AASLD LiverLearning®, Su Wang, 144691
Plasma markers of liver cell death Keratin 18 (K18) and its caspase-cleaved fragment (cK18) are novel biomarkers to define progression of cirrhotic patients with acute decompensation to acute on chronic liver failure (ACLF) and mortality
AASLD LiverLearning®, Stewart Macdonald, 144947
Factors predictive of infections in acute decompensated cirrhosis patients may help identify infections sooner than later: value of SIRS criteria upon admission.
AASLD LiverLearning®, Sandeep Yarlagadda, 144948
Impaired Anti-HBV Vaccine Response In Non-Cirrhotic Chronic HCV Patients Is Not Overcome By Double Or Additional (4th) Dosing
AASLD LiverLearning®, Mário Pessôa, 144704
The level of HBV RNA in serum as a novel marker for the phase of chronic hepatitis B virus (HBV) infections
AASLD LiverLearning®, Florian van Boemmel, 144706
Chronic Outpatient Intravenous Albumin Decreases Hospitalization and Mortality in Patients with Cirrhosis and Refractory Ascites or Anasarca
AASLD LiverLearning®, Brooke Osborne, 144962
Obstetricians’ Knowledge and Practices Regarding Chronic Hepatitis B in Pregnancy
AASLD LiverLearning®, Bolin Niu, 144707
Time for a new, more inclusive endpoint for treatment of type 1 hepatorenal syndrome (HRS-1)? Small changes in serum creatinine (SCr) of >20% are equivalent to HRS reversal (HRSR) in predicting survival and need for renal replacement therapy (RRT) during
AASLD LiverLearning®, Thomas Boyer, 144963
Development of Hepatocellular Carcinoma after Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B
AASLD LiverLearning®, Sun Hong Yoo, 144708
External Abdominal Compression for Refractory Ascites: A Pilot Study
AASLD LiverLearning®, Patrick Chen, 144964
Nearly One Third of Asian Adults with Treatment Naïve Chronic Hepatitis B Virus (HBV) Infection with Elevated HBV DNA and Normal Alanine Aminotransferase Have Significant Hepatic Fibrosis
AASLD LiverLearning®, Robert Wong, 144721
Profiling Changes in Neutrophil-Lymphocyte Ratio in Response to Antiviral Therapy for Chronic Hepatitis B Infection
AASLD LiverLearning®, Marnonette Marallag, 144722
Renal replacement therapy in acute on chronic liver failure - Outcomes and predictors of survival
AASLD LiverLearning®, Suman Nayak, 144978
Proportion of Pre-Core Mutation Determines HBV Phenotype after HBeAg Seroconversion
AASLD LiverLearning®, Daniel Suarez, 144723
Predicting mortality utilizing MELD and MELD-Na after Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Faruq Pradhan, 144979
Non-invasive prediction of liver disease in a multi-genotype cohort of hepatitis B e antigen negative patients
AASLD LiverLearning®, Gayatri Chakrabarty, 144724
Survival Benefit and Morbidity With Terlipressin Plus Albumin in Treating Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
AASLD LiverLearning®, Harsha Moole, 144980
Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis—Interim Results From The Lowr Hdv-2 Study.
AASLD LiverLearning®, Cihan Yurdaydin, 144737
Comparison of the efficacy of entecavir and tenofovir monotherapy for the treatment of treatment -naïve patients with hepatitis B virus
AASLD LiverLearning®, Young Kul Jung, 144738
The clinical candidate MTL-CEBPA leads to significant reduction in ascites and improvement in overall survival in a CCl4-induced acute liver failure model.
AASLD LiverLearning®, Vikash Reebye, 144994
High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up
AASLD LiverLearning®, Femke Stelma, 144739
Hepatic microcirculatory phenotype in aging: mildly dysfunctional in health but markedly deteriorated in chronic liver injury
AASLD LiverLearning®, Raquel Maeso Diaz, 144995
Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection
AASLD LiverLearning®, Andrew Vaillant, 144740
Serum Creatinine for Given MELD Score Impacts Outcomes After Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Tom Catron, 144996
HBsAg-redirected T cells have potent antiviral activity in HBV-infected human liver chimeric mice
AASLD LiverLearning®, Robert Kruse, 144753
High Frequency of Flares in Alanine Aminotransferase (ALT) And Hepatitis B Virus (HBV) DNA During Pregnancy And Postpartum in Women With Chronic Hepatitis B (CHB) Who Discontinued Therapy Prior to or During Early Pregnancy
AASLD LiverLearning®, Christine Chang, 144754
HBV Genotype Differences in Treatment Response to TAF and TDF
AASLD LiverLearning®, Maria Buti, 144755
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection
AASLD LiverLearning®, Xiang-Yong Li, 144756
Silibinin treatment for hepatitis D: in vitro and in vivo.
AASLD LiverLearning®, Eve-Isabelle Pecheur, 144769
Population Pharmacokinetic Analysis of Peginterferon Alfa-2a (40KD) Supports the use of Bsa-Category Based Dosing Regimen in Children with Chronic Hepatitis B: PEG-B-ACTIVE Pharmacokinetic Substudy
AASLD LiverLearning®, Celine Sarr, 144770
Characterization of host, viral, and treatment-related factors associated with antiviral efficacy of tenofovir alafenamide (TAF) and tenofovir disporoxil (TDF)
AASLD LiverLearning®, Edward Gane, 144771
Identification of novel CD8+ T-cell epitopes in HLA-A24-positive patients with hepatitis B virus.
AASLD LiverLearning®, Kiichiro Kaji, 144772
Factors associated with adherence to hepatocellular carcinoma surveillance in patients undergoing hepatitis B anti-viral therapy in Australia.
AASLD LiverLearning®, Suzanne Sheppard-Law, 144530
A novel method for accurate quantification of intra-hepatic HBV cccDNA in liver biopsy specimens and its application for predicting patient’s response to interferon-α2a therapy
AASLD LiverLearning®, Yong Liao, 144786
Fatigue & Hepatitis C: A Focus Group Study
AASLD LiverLearning®, Zobair Younossi, 144531
Clinical Impact of Hepatic Steatosis in Patients with Chronic Hepatitis B Infection on Tenofovir Therapy
AASLD LiverLearning®, Jeong Eun Song, 144787
The effect after cessation of nucleos(t)ide analog(ue)s for chronic hepatitis B virus infection patients who had serum HBsAg negative is durable
AASLD LiverLearning®, Xiang-Yong Li, 144788
Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers (CpAMs)
AASLD LiverLearning®, Qi Huang, 144789
Clinical features and long term outcomes of Autoimmune hepatitis (AIH) and its overlap with Primary Sclerosing Cholangitis (PSC)
AASLD LiverLearning®, Guan Wee Wong, 144545
In Well-Controlled Autoimmune Hepatitis Treatment Withdrawal May Be Safely Accomplished without Liver Biopsy Guidance
AASLD LiverLearning®, Yilien Alonso, 144546
Time-varying Serum Gradient of Hepatitis B Surface Antigen after Cessation of Nucleos(t)ide Analogues and Risk of Off-therapy Relapse
AASLD LiverLearning®, Yao-Chun Hsu, 144802
The Role of Repeat Liver Biopsies in Autoimmune Hepatitis (AIH) at a Tertiary HPB Centre in South England, UK: Current experience, clinical dilemmas and recommendations
AASLD LiverLearning®, Claire Kelly, 144547
Patients with HCV GT 1/4 infection and compensated cirrhosis, without baseline NS5A RASs, could be treated with SOF + NS5A inhibitor for 12 weeks without RBV
AASLD LiverLearning®, Slim Fourati, 144803
Factors affecting clinical trial enrollment in patients with hepatitis C virus (HCV)
AASLD LiverLearning®, Vijaya L. Rao, 144804
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
AASLD LiverLearning®, George Ioannou, 144805
Oncostatin M plays a crucial role in liver fibrogenesis by regulating cooperation between hepatic stellate cells and macrophages
AASLD LiverLearning®, Michitaka Matsuda, 144561
Protective role of specific pathogen free microbiota in bile duct ligated and CCL4 treated mice
AASLD LiverLearning®, Sheida Moghadamrad, 144562
Efficacy and safety of sofosbuvir and ledipasvir in the treatment of elderly Japanese patients with hepatitis C genotype 1 infected.
AASLD LiverLearning®, Kenji Nagata, 144818
The role of Thy-1 in the pathogenesis of cholestatic liver fibrosis
AASLD LiverLearning®, Yukinori Koyama, 144563
Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic HCV Genotype 3 Infection
AASLD LiverLearning®, Christophe Hezode, 144819
Ribavirin plasma level is an independent predictor for sustained virologic response in difficult to treat hepatitis C-infected patients treated with direct-acting antivirals + ribavirin combination (HepNed study 002)
AASLD LiverLearning®, Faydra Lieveld, 144820
The efficacy and safety of sofosbuvir plus ribavirin with or without peg-interferon in treatment of naïve and experienced Vietnamese patients with chronic genotype 1 and 6 HCV infection.
AASLD LiverLearning®, Thu Thuy Pham Thi, 144821
Phenotype of human intrahepatic innate lymphoid cell subsets in health and disease
AASLD LiverLearning®, Ye Htun Oo, 144577
Toll like receptor 4 mediates an immunosuppressive effect of hepatic stellate cells during hepatocellular carcinogenesis
AASLD LiverLearning®, Jinsheng Guo, 144578
HCV therapy selector webapp: an uniquely simple tool for evidence-based therapy selection for patients with chronic hepatitis C virus infection
AASLD LiverLearning®, Raoel Maan, 144834
Inhibition of vascular endothelial growth factor signaling facilitates recovery from acute ethanol-induced liver injury in zebrafish
AASLD LiverLearning®, Chunyue Yin, 144579
Multi-center experience using Sofosbuvir & Ribavirin with and without pegylated interferon to treat hepatitis C patients with and without liver cirrhosis (RESiP Study: Real-life Experience with Sofosbuvir in Pakistan)
AASLD LiverLearning®, Javed Farooqi, 144835
Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
AASLD LiverLearning®, Francesca Ceccherini-Silberstein, 144836
Use of Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) in Genotype 1 (GT 1) HCV-infected Patients Post Liver Transplant (LT): Evaluation of Several Real-world Datasets (RWD)
AASLD LiverLearning®, Marc Bourliere, 144837
LPS aggravates fibrosis only in the early onset but not in the end stage of liver fibrosis
AASLD LiverLearning®, Suriguga S, 144593
Downregulated A-Kinase Anchoring Protein 12 (AKAP12) in Sinusoidal Endothelium is Associated with Vascular Changes in Hepatic Fibrogenesis of Various Etiologies
AASLD LiverLearning®, Hye Shin Lee, 144594
Prevalence and Factors Associated with Genotypic Resistance-Associated Variants of HCV Genotype 1 in Ledipasvir/Sofosbuvir Relapsers - A Multicenter Study.
AASLD LiverLearning®, Omar Mousa, 144850
Combination therapy with mesenchymal stem cells and macrophages from bone marrow shows favorable outcome in mouse CCl4-induced liver cirrhosis model
AASLD LiverLearning®, Yusuke Watanabe, 144595
Glomerular Filtration Rate Change During HCV with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected Patients Treated with Tenofovir ± Boosted Protease Inhibitor
AASLD LiverLearning®, Cristina Soeiro, 144851
Quality of life of HCV patients treated with new direct-acting antiviral agents decreases during the first week of treatment and is inversely correlated with HCV viral load: a single-center prospective study
AASLD LiverLearning®, Christophe Renou, 144852
Attention to “Cirrhosis” in the News Media in 36 Countries Worldwide: Insufficient Awareness of Non-alcoholic Compared to Alcoholic Liver Disease.
AASLD LiverLearning®, Nambi Ndugga, 144609
Cost-effectiveness of an HCV screening and treatment linkage intervention in US methadone maintenance treatment (MMT) programs
AASLD LiverLearning®, Benjamin Linas, 144610
Response to Direct Acting Antivirals in African American Liver and Kidney Transplant Recipients with Genotype 1 Hepatitis C Infection
AASLD LiverLearning®, Heather Snyder, 144866
Cost effectiveness analysis of potentially curative treatments for hepatocellular carcinoma with person-level data in a Canadian setting
AASLD LiverLearning®, Hla-Hla (Rosie) Thein, 144611
Ledipasvir-Sofosbuvir for the treatment of Hepatitis C Virus Genotype 1 and 4 Post Renal Transplantation
AASLD LiverLearning®, Faisal Abaalkhail, 144867
Impact of HCV Therapy with Direct-Acting Antivirals on Lipid Profiles
AASLD LiverLearning®, Pooja Dharwadkar, 144868
Improving HCV Testing in Alignment with Current Guidelines: Technology Alone is Not the Answer
AASLD LiverLearning®, Sara Miller, 144625
Mortality from Multidrug Resistant Colonization or Infection in Hospitalized Patients with Cirrhosis
AASLD LiverLearning®, Monica Schmidt, 144626
Sofosbuvir + simeprevir +/- ribavirin treatment is efficient in genotype 4 chronic hepatitis C patients: results of a large international cohort
AASLD LiverLearning®, Christophe Moreno, 144882
Potential Conflicts of Interest for Authors of Recent AASLD Clinical Practice Guidelines
AASLD LiverLearning®, Audrey Dillon, 144627
Effectiveness of Sofosbuvir/Ledipasvir and Sofosbuvir/Simeprevir for the Treatment of Hepatitis C Genotype-1: Real World Analysis
AASLD LiverLearning®, Shirin Nafisi, 144883
Efficacy of All-Oral HCV Therapy in People Who Inject Drugs (PWID)
AASLD LiverLearning®, Brian Conway, 144884